|Bid||107.01 x 800|
|Ask||107.13 x 900|
|Day's range||106.44 - 108.05|
|52-week range||79.11 - 121.53|
|Beta (5Y monthly)||0.79|
|PE ratio (TTM)||28.88|
|Earnings date||28 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||5.20 (4.86%)|
|Ex-dividend date||14 Oct 2021|
|1y target est||127.01|
AbbVie (NYSE: ABBV) recently announced a collaboration with Regenxbio (NASDAQ: RGNX) to develop a gene therapy targeting wet age-related macular degeneration. The deal could be worth up to nearly $1.8 billion including milestone payments. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss why AbbVie is teaming up with Regenxbio.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine.